利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

44 条记录 (耗时 0.023 秒)

    Urea-based mixing process for increasing combustion efficiency and reduction of nitrogen oxides (NOx)
    1.
    发明申请
    Urea-based mixing process for increasing combustion efficiency and reduction of nitrogen oxides (NOx) 有权
    用于提高燃烧效率和减少氮氧化物（NOx）的基于尿素的混合方法

    公开(公告)号：US20070003890A1

    公开(公告)日：2007-01-04

    申请号：US11455924

    申请日：2006-06-19

    申请人： Brian Higgins

    发明人： Brian Higgins

    IPC分类号： F23D11/44

    CPC分类号： F23C5/32 ,  F23J7/00 ,  F23L7/002 ,  F23L9/04

    摘要： A method for reducing NOx formation, including the steps of: providing a furnace with a plurality of secondary air injection ducts, asymmetrically positioned in an opposing manner; injecting fuel with primary air through a first stage prior to injection of a second air; injecting secondary air and aqueous urea solution through the plurality of reagent injection ducts; controlling the asymmetrical injection to produce a high velocity mass flow and a turbulence resulting in dispersion of the urea solution into the combustion space, thereby providing reduced NOx formation in the combustion process.

    摘要翻译： 一种用于减少NOx形成的方法，包括以下步骤：为炉提供多个二次空气喷射管道，以相对的方式不对称地定位; 在注入第二空气之前通过第一阶段向一次空气喷射燃料; 通过所述多个试剂注入管道注入二次空气和尿素水溶液; 控制不对称注入以产生高速质量流和湍流，导致尿素溶液分散到燃烧空间中，从而在燃烧过程中提供减少的NOx形成。

    Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor
    3.
    发明申请
    Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor 有权
    联合治疗顺铂和表皮生长因子受体激酶抑制剂

    公开(公告)号：US20050271747A1

    公开(公告)日：2005-12-08

    申请号：US11145495

    申请日：2005-06-03

    申请人： Brian Higgins ,  Kenneth Kolinsky

    发明人： Brian Higgins ,  Kenneth Kolinsky

    IPC分类号： A61K31/4706 ,  A61K31/496 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K33/24 ,  A61K38/50

    CPC分类号： A61K31/519 ,  A61K31/4706 ,  A61K31/496 ,  A61K31/517 ,  A61K31/5377 ,  A61K33/24 ,  A61K38/50 ,  A61K2300/00

    摘要： The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and cisplatin combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and cisplatin combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).

    摘要翻译： 本发明提供了一种用于治疗患者的肿瘤或肿瘤转移的方法，其包括向所述患者同时或依次施用治疗有效量的EGFR激酶抑制剂和顺铂组合，所述另外的药物或治疗剂， 癌症药物或放射治疗。 本发明还包括药物组合物，其由EGFR激酶抑制剂和顺铂组合与药学上可接受的载体组合组成。 可用于实施本发明的EGFR激酶抑制剂的优选实例是化合物厄洛替尼HCl（也称为Tarceva TM）。

    COMBINATION THERAPY
    5.
    发明申请
    COMBINATION THERAPY 有权
    组合治疗

    公开(公告)号：US20120148533A1

    公开(公告)日：2012-06-14

    申请号：US13313042

    申请日：2011-12-07

    申请人： Kapil Dhingra ,  Brian Higgins ,  Kenneth Kolinsky ,  Richard J. Lee ,  Brian Lestini ,  Kathryn Packman ,  Fei Su

    发明人： Kapil Dhingra ,  Brian Higgins ,  Kenneth Kolinsky ,  Richard J. Lee ,  Brian Lestini ,  Kathryn Packman ,  Fei Su

    IPC分类号： A61K38/21 ,  A61P35/00

    CPC分类号： A61K38/212 ,  A61K31/437 ,  A61K38/21 ,  A61K2300/00

    摘要： The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.

    摘要翻译： 本发明涉及丙烷-1-磺酸{3- [5-（4-氯 - 苯基）-1H-吡咯并[2,3-b]吡啶-3-羰基-2,4-二氟 - 苯基] - 酰胺}或其药学上可接受的盐，以及用于治疗患有增殖性疾病，特别是实体瘤例如结肠直肠癌，黑素瘤和甲状腺癌的患者的干扰素。 特别地，本发明涉及这样的治疗，其中干扰素是聚乙二醇化干扰素α-2a，该病症是含有V600E b-Raf突变的黑素瘤。

    Combined treatment with irinotecan and an epidermal growth factor receptor kinase inhibitor
    10.
    发明申请
    Combined treatment with irinotecan and an epidermal growth factor receptor kinase inhibitor 审中-公开
    伊立替康和表皮生长因子受体激酶抑制剂联合治疗

    公开(公告)号：US20050272737A1

    公开(公告)日：2005-12-08

    申请号：US11144855

    申请日：2005-06-03

    申请人： Jianping Chen ,  Brian Higgins ,  Kenneth Kolinsky

    发明人： Jianping Chen ,  Brian Higgins ,  Kenneth Kolinsky

    IPC分类号： A61K31/4706 ,  A61K31/4745 ,  A61K31/498 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K39/395 ,  A61K45/06

    CPC分类号： A61K31/519 ,  A61K31/4706 ,  A61K31/4745 ,  A61K31/517 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and irinotecan combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and irinotecan combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).

    摘要翻译： 本发明提供了一种用于治疗患者的肿瘤或肿瘤转移的方法，其包括向所述患者同时或相继施用治疗有效量的EGFR激酶抑制剂和伊立替康组合，所述另外的药物或治疗剂， 癌症药物或放射治疗。 本发明还包括由EGFR激酶抑制剂和伊立替康组合与药学上可接受的载体组合的药物组合物。 可用于实施本发明的EGFR激酶抑制剂的优选实例是化合物厄洛替尼HCl（也称为Tarceva TM）。